Ampio Pharmaceuticals, Inc.

• Ominous Competition For Lucentis and Eylea

  By Richard Allen - November 23, 2012 | Tickers: AMPE, NVS, REGN, RHHBY

  Lucentis from Roche (NASDAQOTH: RHHBY) and Novartis (NYSE: NVS), and Eylea from Regeneron (NASDAQ: REGN) were recently approved by the FDA and combined are already producing revenues of close to $2.5 billion.  The shares of Roche and Novartis may be down a bit from their recent highs one month ago, but Regeneron continues to streak to new highs and give shareholders a spectacular ride.

  Lucentis and Eylea are both more »

• Cover Story In Retina Today Reveals Ominous Competition For $1.7 Billion Lucentis

  By Dave Coennen - November 8, 2012 | Tickers: AMPE, NVS, REGN

  Optina in Oral Form Likely to Become Preferred Treatment For Diabetic Macular Edema Over Monthly Injection Into the Eye

  Diabetic Macular Edema "DME" threatens the eyesight of millions of patients every year and the number is growing rapidly driven by soaring rates of diabetes. In DME, the blood vessels in the retina leak blood and fluids into delicate retinal tissue where the sight receptors reside causing swelling of the retina more »

• Ampio: Heading in the Right Direction

  By John Eastman - May 1, 2012 | Tickers: AMPE

  What is novel about the company’s strategy is that their product pipeline is largely based on developing new uses for previously approved drugs and new molecular entities ("NMEs").